Cargando…

Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells

In early 2020, the novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and rapidly propagated worldwide causing a global health emergency. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) protein for cell entry, followed by proteolytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majidipur, Amene, Morin-Dewaele, Margot, Gaspar Lopes, Jeanne, Berry, Francois, Fouchet, Julien, Bartier, Sophie, Dufros Duval, Anais, Soyeux, Pascale, Huet, Eric, Louis, Bruno, Coste, André, Béquignon, Émilie, Saldana, Carolina, Le Corvoisier, Philippe, Destouches, Damien, Pawlotsky, Jean-Michel, de la Taille, Alexandre, Vacherot, Francis, Bruscella, Patrice, Firlej, Virginie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961850/ https://www.ncbi.nlm.nih.gov/pubmed/36834705 http://dx.doi.org/10.3390/ijms24043288

Ejemplares similares

Proviral role of human respiratory epithelial cell‐derived small extracellular vesicles in SARS‐CoV‐2 infection
por: Berry, François, et al.
Publicado: (2022)

Régulation de TMPRSS2 par la voie des androgènes et implications dans l’infection SARS-CoV-2
por: Firlej, V., et al.
Publicado: (2021)

Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance
por: Saldana, Carolina, et al.
Publicado: (2021)

Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry
por: Morin-Dewaele, Margot, et al.
Publicado: (2022)

Overexpression of Nucleolin and Associated Genes in Prostate Cancer
por: Firlej, Virginie, et al.
Publicado: (2022)

Oncostatin M Contributes to Airway Epithelial Cell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps
por: Carsuzaa, Florent, et al.
Publicado: (2023)

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer
por: Destouches, Damien, et al.
Publicado: (2016)

Sublabial bioactive glass implantation for the management of primary atrophic rhinitis and empty nose syndrome: Operative technique
por: Hassan, Charles‐Henri, et al.
Publicado: (2021)

Hypothyroidism caused by apalutamide
por: Daviduck, Quinn, et al.
Publicado: (2023)

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)
por: Softic, Laurent, et al.
Publicado: (2020)

The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer
por: Blanc, Charly, et al.
Publicado: (2022)

Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells
por: Sirab, Nanor, et al.
Publicado: (2013)

Psoriatic Skin Lesions after Apalutamide Treatment
por: MIYAGAWA, Fumi, et al.
Publicado: (2022)

FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review
por: Fieux, Maxime, et al.
Publicado: (2021)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Pathogenesis of chronic rhinosinusitis with nasal polyps: role of IL-6 in airway epithelial cell dysfunction
por: Bequignon, Emilie, et al.
Publicado: (2020)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
por: Alkhudair, Nora A.
Publicado: (2019)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Urinary extracellular vesicles contain mature transcriptome enriched in circular and long noncoding RNAs with functional significance in prostate cancer
por: Almeida, Anna, et al.
Publicado: (2022)

Viruses and miRNAs: More Friends than Foes
por: Bruscella, Patrice, et al.
Publicado: (2017)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?
por: Bequignon, Emilie, et al.
Publicado: (2019)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration
por: Yu, Alex, et al.
Publicado: (2021)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
por: Eberli, Daniel, et al.
Publicado: (2022)

Objective diagnosis of internal nasal valve collapse by four‐phase rhinomanometry
por: Gagnieur, Pierre, et al.
Publicado: (2022)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Apalutamide‐associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy
por: Tohi, Yoichiro, et al.
Publicado: (2021)

Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer
por: Honda, Tomoko, et al.
Publicado: (2022)

Synthesis of Multifunctional Polymersomes Prepared by Polymerization-Induced Self-Assembly
por: Phan, Hien, et al.
Publicado: (2023)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Apalutamide: A Case Presentation
por: Martin, Gabriella, et al.
Publicado: (2023)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_736ab1mcvp6atb2kdepd6si68i